• Chat
  • Dashboard
  • Daily Briefing
  • Discover
    • Feedback
    • Sign In
    Sign InSign Up

    How Two Rivals Undercut J&J's Beat And Big Guidance - Investor's Business Daily

    AI Summary1 min read

    TL;DR

    Johnson & Johnson's strong 2025 earnings and 2026 guidance were overshadowed by competitive moves from two rivals, impacting investor sentiment.

    Tags

    Johnson & Johnsonearnings reportoncology salesmedtech growthWall Street estimates
    1. How Two Rivals Undercut J&J's Beat And Big Guidance  Investor's Business Daily
    2. What you need to know about Johnson & Johnson’s fourth-quarter and full-year 2025 earnings report  Johnson & Johnson
    3. J&J wants to be the leader in the cancer fight. Its strategy is starting to pay off as oncology sales top $25 billion in 2025.  MarketWatch
    4. J&J’s cardiovascular business boosts medtech growth in 2025  MedTech Dive
    5. Johnson & Johnson forecasts 2026 profit above Wall Street estimates  CNBC

    Thursday, January 22, 2026 12:02 AM

    Visit Website
    website-logo

    Top stories - Google News

    Google News

    channel icon
    Related Articles

    Duke’s Darian Mensah can enter transfer portal but can’t play elsewhere, judge’s order says - The Athletic - The New York Times

    Jan 22, 2026

    Autopsy report classifies ICE detainee’s death as a homicide - The Washington Post

    Jan 22, 2026

    Oscar nominations are this morning. ‘Sinners’ could make history - AP News

    Jan 22, 2026

    China Wins as Trump Cedes Leadership of the Global Economy - The New York Times

    Jan 22, 2026
    xgithub
    logo

    Copyright © 2022-2026 - Aetos.AI